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OBJECTIVES We sought to study atrial vulnerability in patients with Brugada syndrome.
BACKGROUND Atrial fibrillation (AF) often occurs in patients with Brugada syndrome, but atrial vulnera-
bility in Brugada syndrome has not been evaluated.
METHODS The patient group consisted of 18 patients with Brugada syndrome. The control group
consisted of 12 age- and gender-matched subjects who had neither organic heart disease nor
AF episodes. The incidence and clinical characteristics of AF were evaluated in all 18 patients
with Brugada syndrome, and an electrophysiologic study was performed in all 12 control
subjects and in 14 of the 18 patients with Brugada syndrome. The atrial effective refractory
period of the right atrium (RA-ERP), intra-atrial conduction time (conduction time from the
stimulus at the right atrium to atrial deflection at the distal portion of the coronary sinus),
duration of local atrial potential, and repetitive atrial firing (occurrence of two or more
premature atrial complexes after atrial stimulation) were studied.
RESULTS Spontaneous AF occurred in 7 of the 18 patients with Brugada syndrome but in none of the
control subjects. The RA-ERP was not different between the two groups. The intra-atrial
conduction time was increased in the Brugada syndrome group versus the control group
(168.4  17.5 vs. 131.8  13.0 ms, p  0.001). The duration of atrial potential at the
RA-ERP was prolonged in the Brugada syndrome group versus the control group (80.3 
18.0 vs. 59.3  9.2 ms, p  0.001). Repetitive atrial firing was induced in nine patients with
Brugada syndrome and in six control subjects. Atrial fibrillation was induced in eight patients
with Brugada syndrome but in none of the control subjects. In patients with Brugada
syndrome without spontaneous AF, the intra-atrial conduction time and duration of atrial
potential were also increased.
CONCLUSIONS Atrial vulnerability is increased in patients with Brugada syndrome. Abnormal atrial
conduction may be an electrophysiologic basis for induction of AF in patients with Brugada
syndrome. (J Am Coll Cardiol 2002;40:1437–44) © 2002 by the American College of
Cardiology Foundation
The Brugada syndrome is characterized by ST-segment
elevation in leads V1 to V3 with a right bundle branch block
pattern and nocturnal sudden cardiac death due to ventric-
ular fibrillation (1–5).
Arrhythmias such as premature ventricular contraction,
monomorphic ventricular tachycardia, polymorphic ventric-
ular tachycardia (6–8), and ventricular fibrillation have been
reported. In addition, atrial arrhythmia has also been re-
ported in patients with Brugada syndrome (2,9–13). Re-
cently, it has been reported that mutations of the sodium
channel gene cause Brugada syndrome (4–19). If Brugada
syndrome is a sodium channel disease, it is possible that an
electrical abnormality of the myocardium might exist not
only in the ventricular myocardium (5,20) but also in the
atrial myocardium. Thus, in this study, we evaluated atrial
vulnerability in patients with Brugada syndrome.
METHODS
Patients. The patient group consisted of 18 patients with
Brugada syndrome (Table 1). The patients were all men,
ranging in age from 33 to 71 years (mean 49  11). All of
the patients with Brugada syndrome showed the typical
electrocardiographic (ECG) “Brugada sign,” which was
defined previously (4). Ten patients with Brugada syndrome
had experienced syncopal episodes or had a family history of
sudden cardiac death. The other eight patients were asymp-
tomatic and had no family history of sudden cardiac death.
The control group consisted of 12 age- and gender-matched
subjects (mean age 48 10 years [range 35 to 60]) who had
no sign of the Brugada-type ECG change and no episodes
of atrial fibrillation (AF), nor could AF be induced by pro-
grammed electrical stimulation. The 12 subjects in the control
group included 9 patients with paroxysmal supraventricular
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tachycardia without manifest Wolf-Parkinson-White syn-
drome and 3 patients with idiopathic ventricular tachycardia.
Study protocol. EVALUATION OF INCIDENCE OF AF. The
occurrence of AF was evaluated by clinical follow-up (every
month), observing the patient’s symptoms, and 24-h Holter
ambulatory ECG recording. Continuous ECG monitoring
was performed from two to three weeks during administra-
tion.
ELECTROPHYSIOLOGIC STUDY. After obtaining the pa-
tients’ written, informed consent, an electrophysiologic
study was performed in all 12 control subjects and in 14 of
18 patients with Brugada syndrome. After right femoral and
right carotid venous access was obtained, three quadripolar
electrode catheters (6F) with an interelectrode distance of 5
mm (EP Technologies, Boston Scientific, Inc., Sunnyvale,
California) were positioned in the right atrial appendage
(RAA), His bundle region, and right ventricle, and an
octopolar catheter (6F) with an interelectrode distance of
2.5 mm (EP Technologies, Boston Scientific, Inc.) was
positioned into the coronary sinus (CS). Endocardial po-
tentials were recorded by bipolar and filtered to record
frequencies of 30 to 400 Hz. Programmed electrical stim-
ulation was performed at an intensity of twice the threshold
and for 2 ms in duration through the distal electrodes in the
RAA, using the SEC3105 Nihon-Koden pulse generator. A
premature stimulus (S2) was delivered after eight beats of
drive pacing (S1) at a basic cycle length of 600 ms. The
S1–S2 interval was decreased in 10-ms steps until the
effective refractory period (ERP) of the RAA was reached.
The first deflection in amplified recordings of the atrial
electrograms was taken as the onset of atrial depolarization.
Atrial vulnerability was evaluated by the ERP of the
RAA, intra-atrial conduction time (CT) and conduction
delay (CD) during the basic cycle length of S1 and extra-
stimulus of S2, duration of the local right atrial potential
during the basal cycle length of S1 and extrastimulus of S2,
and repetitive atrial firing (RAF) and induced AF in
response to S2.
The occurrence of premature atrial contraction (PAC)
and AF was evaluated at baseline and after infusion of 2 g
isoproterenol in all control subjects and patients with
Brugada syndrome in whom an electrophysiologic study had
been performed.
DEFINITIONS. The ERP was defined as the longest cou-
pling interval (S1–S2) at which the stimulus failed to
propagate a response. The intra-atrial CT was defined as
the interval from the stimulus to the atrial deflection at the
distal portion of the CS. The CD was defined as the difference
between the CT at S2 and that at S1, and a positive CD was
defined as an increase of 20 ms in CT at S2 compared with
that at S1. The CD zone was defined as the range of the
coupling interval that shows a positive CD (21–23).
Abbreviations and Acronyms
AF  atrial fibrillation
CD  conduction delay
CS  coronary sinus
CT  conduction time
ERP  effective refractory period
FAA  fragmented atrial activity
PAC  premature atrial contraction
RA  right atrium/atrial
RAA right atrial appendage
RAF  repetitive atrial firing
Table 1. Characteristics of Patients With Brugada Syndrome
Pt.
No. Age Gender EPS
VF/
Syncope*
Family
History†
VA
Induction‡
AF
(Spont.)§
AF
(EPS) Therapy
Follow-Up
(month)
AF
Frequency
1 33 M       ICD 18 0
2 36 M       None 18 0
3 39 M       ICD 16 0
4 40 M       None 60 0
5 41 M       ICD 63 0
6 41 M       ICD 27 0
7 45 M       ICD 12 0
8 51 M       None 72 0
9 52 M       None 48 0
10 55 M       ICD  Disopyramide 38 0
11 45 M       ICD 130 0
12 42 M       None 23 1
13 55 M       ICD  Disopyramide 22 1
14 55 M    NA  NA None 53 1/M
15 56 M    NA  NA None 36 2
16 58 M       ICD 17 3
17 70 M    NA  NA None 12 4
18 71 M    NA  NA ICD 40 8
*History of syncope or ventricular fibrillation (VF). †Family history of sudden death or Brugada syndrome. ‡Induction of VF or ventricular tachycardia by programmed electrical
stimulation (PES). §History of spontaneous atrial fibrillation (AF) attack. Induction of AF by PES.
ICD  implantable cardioverter-defibrillator; EPS  electrophysiologic study; NA  not assessed; VA  ventricular arrhythmias.
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The presence of fragmented atrial activity (FAA) was
defined as the duration of A2 at the ERP of RAA/duration
of A1 150%. The FAA zone was defined as the range of
the coupling interval that resulted in FAA (24–26). Repet-
itive atrial firing was defined as the occurrence of two or
more premature atrial complexes (21,22).
Induced AF was defined as AF that was induced by
programmed electrical stimulation and persisted for 30 s.
Spontaneous AF was defined as AF detected by 12-lead
electrocardiography or ambulatory ECG monitoring with-
out any maneuvers, including programmed electrical stim-
ulation and drug stress tests.
Statistical analysis. Quantitative data are expressed as the
mean value  SD. The statistical significance of the
differences was analyzed by using the Student t test for
unpaired values. A value of p  0.05 was considered as
statistically significant.
RESULTS
Clinical characteristics and incidence and frequency of
AF in patients with Brugada syndrome. Spontaneous
paroxysmal AF was detected in 7 (39%) of 18 patients with
Brugada syndrome: 5 with ventricular fibrillation or a
positive family history of sudden death and 2 asymptomatic
patients with Brugada syndrome and no family history of
sudden death. All patients had a paroxysmal attack of AF,
and none of the patients showed persistent or chronic AF.
The frequency of AF attack was low in the majority of
patients with Brugada syndrome (Table 1). The patients’
mean age of AF onset was 56  11 years.
The Holter ambulatory ECG showed that PAC rarely
occurred in patients with Brugada syndrome; mean, median,
and range of PACs were 5  6, 12, and 0 to 23/day,
respectively. Initiation of AF was detected in Patient 18
only; AF was followed by rapid firing of PAC, but no PACs
were observed before the occurrence of AF (Fig. 1).
Isoproterenol infusion. Isoproterenol infusion did not in-
duce any PACs or AF in the control subjects. Isoproterenol
infusion induced PAC and AF in only one patient with
Brugada syndrome (Patient 18), but neither PAC nor AF
occurred in any of the other patients.
Atrioventricular conduction. The ventricular response
during spontaneous AF in patients with Brugada syndrome
was relatively slow (Fig. 2); the mean heart rate during AF
was 63  10 beats/min.
The AH interval was significantly prolonged (p  0.001)
in the Brugada syndrome group (96.9  10.6 ms), as
compared with that in the control group (73.8  15.3 ms).
The HV interval was prolonged in the Brugada syndrome
group, but not significantly so (41.3 6.7 vs. 36.2 6.5 ms
in control group, p  0.057). The ERP of atrioventricular
node was prolonged in patients with Brugada syndrome
(350.7  69.9 vs. 271.8  42.0 ms in control group, p 
0.001) (Fig. 2). The one-to-one conduction of the
Figure 1. Initiation of spontaneous atrial fibrillation (AF) on the Holter ambulatory electrocardiogram. (a) Spontaneous AF occurred at midnight.
Premature atrial contraction was not observed before the occurrence of AF. (b) Initiation of paroxysmal AF. Paroxysmal atrial contraction occurred on the
T-wave at the initiation of AF. Coarse fibrillatory waves succeeded and degenerated into fine and irregular f waves.
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atrioventricular node was slower in the Brugada syndrome
group (133  17 beats/min) than in the control group (173
 31 beats/min, p  0.01).
Induction of RAF and AF. Repetitive atrial firing was
induced in nine patients with Brugada syndrome (64.3%)
and in six control subjects (50%), and there was no signif-
icant difference between the two groups. However, AF was
induced in 8 (57.1%) of 14 patients with Brugada syndrome
and in none of the control subjects.
Atrial vulnerability. There was no significant difference
between the ERP of the RA in the Brugada syndrome
group and that in the control group (247.1  27.0 vs. 243.3
 20.6 ms) (Fig. 3).
There was no significant difference between the CT at S1
(CT1) in patients with Brugada syndrome and that in the
control group (119.4  15.7 vs. 110.1  19.1 ms), but the
CT at S2 (CT2) in the Brugada syndrome group was
markedly delayed (168.4  17.5 vs. 131.8  13.0 ms in
control group, p  0.001) (Fig. 4).
All of the patients with Brugada syndrome had a positive
CD (49.0  13.7 vs. 21.8  12.2 ms in control group, p 
0.001) (Fig. 3). The CD zone was markedly wider in the
Brugada syndrome group than in the control group (37.1 
14.4 vs. 20.0  11.0 ms, p  0.05).
There was no significant difference between the duration
of A1 in patients with Brugada syndrome and that in the
control group (51.3  6.0 vs. 49.9  5.3 ms in control
group), but the A2 in the Brugada syndrome group was
markedly prolonged compared with that in control group
(80.3  18.0 vs. 59.3  9.2 ms, p  0.01) (Fig. 5). The
prolongation of A2 compared with A1 was more prominent
in the Brugada syndrome group than in the control group
(156.5  27.8% vs. 118.8  12.5%, p  0.001) (Fig. 4).
Half of the patients with Brugada syndrome showed posi-
tive FAA, but only one patient in the control group showed
positive FAA. The FAA zone was wider in Brugada
syndrome (43.0  25.8 ms).
Brugada syndrome patients without a spontaneous AF
attack. Atrial vulnerability in the 11 Brugada syndrome
patients who had no spontaneous AF attack was evaluated.
There was no difference between the ERP of RA in the
Brugada syndrome group without AF and that in the
control group (243.6  28.7 vs. 243.3  20.6 ms). The
indexes of atrial conduction (CT2, CD, and CD zone) were
Figure 2. Spontaneous atrial fibrillation (AF) in patients with Brugada syndrome. Note the slower ventricular response during AF. Lead V2 is shown.
1440 Morita et al. JACC Vol. 40, No. 8, 2002
AF in Brugada Syndrome October 16, 2002:1437–44
prolonged in the Brugada syndrome group without AF
(CT2: 164.5  17.8 ms; CD: 47.3  14.1 ms; CD zone:
37.3  16.2 ms; p  0.05) compared with the control
group. The indexes of local atrial potential were also
prolonged in the Brugada syndrome group without AF (A2:
82.5 19.3 ms; A2/A1: 159.3 30.8%; FAA zone: 48.8
25.9 ms; p  0.0001). In the Brugada syndrome group
without AF, RAF was induced in seven patients (63.6%),
and AF was induced in six patients (54.5%). In all figures,
the data of the Brugada syndrome patients without sponta-
neous AF are represented by solid circles.
DISCUSSION
Polymorphic ventricular tachycardia and ventricular fibril-
lation in patients with Brugada syndrome may be lethal, and
the implantable cardioverter-defibrillator is necessary for the
treatment of Brugada syndrome (1,2). Recently, it has been
Figure 3. Effective refractory period of the atrioventricular node (a) and right atrium (RA) (b). (a) The effective refractory period (ERP) of atrioventricular
node was prolonged in the Brugada syndrome patients with and without atrial fibrillation (AF). (b) There was no significant difference between the ERP
of the RA in the Brugada syndrome group and that in the control group. There was also no significant difference between the ERP of the RA in the Brugada
syndrome patients without AF and that in the control group. Open circles show the Brugada syndrome group with spontaneous AF. Solid circles show
the Brugada syndrome patients without spontaneous AF. The error bars represent the 95% confidence interval. NS  not significant.
Figure 4. (a) Conduction time (CT) at S1 and (b) CT at S2. There was no difference between the CT at S1 in patients with Brugada syndrome and that
in the control group, but the CT at S2 in the Brugada syndrome group was markedly delayed at the right atrium-effective refractory period. The CT1 in
the Brugada syndrome patients without atrial fibrillation (AF) was not different from that in the control group, but the CT2 in these Brugada syndrome
patients was prolonged. (c) Inter-atrial conduction delay. The conduction delay (CD) was markedly prolonged in the Brugada syndrome group, and all
patients with Brugada syndrome showed a positive CD. The CD was also prolonged in the Brugada syndrome patients without AF. Open circles show
the Brugada syndrome patients with spontaneous AF. Solid circles show the Brugada syndrome patients without spontaneous AF. The error bars represent
the 95% confidence interval.
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shown that mutations in the cardiac sodium channel gene,
which result in slow recovery from inactive states of the
sodium channel or sodium channel dysfunction, cause
Brugada syndrome (14–18). This functional change in the
mutational sodium channel will explain the conduction
abnormality of the ventricle and the easy inducibility of
ventricular fibrillation (19), the late activation in the right
ventricular outflow tract, and the abnormal late potential
(20). If a mutation in the cardiac sodium channel does in
fact cause Brugada syndrome (14–16,19), a myocardial
electrical abnormality might exist not only in the ventricular
myocyte but also in the atrial myocyte. We therefore
evaluated the incidence of AF and electrical abnormality in
the atrium in Brugada syndrome. In this study, we found
that atrial vulnerability was enhanced, and the incidence of
AF was increased in patients with Brugada syndrome.
Incidence of AF in Brugada syndrome. Some reports
demonstrated the ECGs of AF in patients with Brugada
syndrome (1–4,10–13), but the exact incidence of AF in
patients with Brugada syndrome is not known. Anzelevitch
et al. (2) reported that only 10% of patients with Brugada
syndrome exhibit paroxysmal AF. In the present study, the
incidence of spontaneous AF in patients with Brugada
syndrome was high (39%), and the incidence of AF induced
by electrical stimulation was also high. These results show
that AF is not rare in patients with Brugada syndrome.
Spontaneous PACs on the Holter ambulatory ECG
recording were rare in our Brugada syndrome group. Iso-
proterenol infusion induced AF in only one patient, but
PAC and AF were not induced by isoproterenol infusion in
the other patients. Therefore, we were not able to evaluate
the trigger of AF and its foci (28,29). Our study indicates
that the incidence of AF in patients with Brugada syndrome
was high, but the frequency of AF attack in each patient was
low. This suggests that the substrate of AF (that is,
abnormal atrial vulnerability) exists and results in random
reentry in the atrium, but the trigger of AF (i.e., PAC) is
rare in patients with Brugada syndrome.
Characteristics of AF and atrioventricular conduction in
Brugada syndrome. Because the ventricular response dur-
ing paroxysmal AF was not rapid in patients with Brugada
syndrome, it was thought that the atrioventricular conduc-
tion was decreased. Furthermore, ECG recordings of AF in
some reports have shown a slow ventricular response during
AF, and the HV interval was also prolonged in patients with
Brugada syndrome (1,3,11,12). In the present study, the
patients with Brugada syndrome showed slower one-to-one
atrioventricular conduction, as measured by atrial pacing, as
compared with the control group, and the AH and HV
intervals and ERP of the atrioventricular node were pro-
longed in patients with Brugada syndrome. Slow atrioven-
tricular conduction results in a slow ventricular response
during AF. Because it is believed that vagal activity plays an
important role in ST-segment elevation and the occurrence
of ventricular fibrillation in patients with Brugada syndrome
(5), the vagal activity might be related to the initiation of
paroxysmal AF and slower atrioventricular conduction in
patients with Brugada syndrome. It has been reported that
cardiac sodium channel mutations caused the long QT
syndrome, Brugada syndrome, and cardiac conduction dis-
ease. Because the sodium channel mutation reported in
Brugada syndrome showed sodium channel dysfunction,
such an abnormal sodium channel would cause an atrioven-
tricular conduction disturbance (27).
Figure 5. Duration of atrial potential and fragmented atrial activity (FAA). (a) Duration of A1. There was no difference between the duration of A1 in
patients with Brugada syndrome and that in the control group. (b) Duration of A2. The duration of A2 in Brugada syndrome was markedly prolonged
compared with that in the control group. The duration of A2 was also markedly prolonged in Brugada syndrome patients without atrial fibrillation (AF).
(c) FAA. The ratio of the duration of A2 to A1 in the Brugada syndrome group was prolonged compared with that in the control group, and half of the
patients with Brugada syndrome showed positive FAA, whereas only one patient in the control group showed positive FAA. The A2/A1 ratio was also
prolonged in Brugada syndrome patients without AF. Open circles show Brugada syndrome patients with spontaneous AF. Solid circles show Brugada
syndrome patients without spontaneous AF. The error bars represent the 95% confidence interval.
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Atrial vulnerability in Brugada syndrome. Atrial vulner-
ability indicates injured atrial myocardial electrical function
that would cause a reentrant circuit. Abnormal atrial vul-
nerability has been found in patients with atrial arrhythmia
associated with sick sinus syndrome (21,24,25) and Wolf-
Parkinson-White syndrome (22). The index of atrial vul-
nerability (21–26,30) includes intra-atrial CD, FAA, RAF,
and atrial refractoriness. The intra-atrial CD indicates
global conduction of the atrial myocardium—that is, a
change in the CT during a stimulus of a constant drive train
and extrastimulus from the right atrium to the left lateral
atrium through the inter-atrial septum. The FAA indicates
local atrial CD—that is, discontinuous propagation and
slowed conduction in a local atrial site. For induction and
persistence of AF, the tissue wavelength determines the
minimal size of a reentrant wavelet, and the persistence of
AF depends on the average total number of wavelets the
tissue can support; intra-atrial and local atrial CD and atrial
refractoriness were also important.
The present study demonstrated that atrial vulnerability,
especially the index of intra-atrial and local atrial conduction
abnormality, was enhanced in patients with Brugada syn-
drome. Atrial vulnerability was enhanced not only in Bru-
gada syndrome patients with AF, but also in Brugada
syndrome patients without AF. Thus, an electrical abnor-
mality of the atrium existed in patients with Brugada
syndrome who did not experience an attack of AF. Thus,
atrial electrical abnormality existed in Brugada syndrome
patients without AF. The atrial ERPs were not different in
patients with Brugada syndrome. These results show that a
conduction abnormality is important for the occurrence of
AF in patients with Brugada syndrome. The occurrence of
RAF in patients with Brugada syndrome indicates that the
atrial conduction abnormality easily induces the reentrant
circuit. Clinically, patients with Brugada syndrome showed
easy inducibility of ventricular fibrillation by programmed
electrical stimulation and a conduction abnormality within
the ventricle. It is possible that similar genetic defects alter
atrial and ventricular electrophysiology in these patients
with Brugada syndrome.
Clinical implications. This study showed that atrial vul-
nerability was enhanced and that the occurrence of parox-
ysmal AF was frequent in patients with Brugada syndrome.
The implantable cardioverter-defibrillator could detect AF
on the electrogram as ventricular fibrillation and would start
cardioversion. The fifth-generation implantable cardioverter-
defibrillator is preferred for patients with Brugada syn-
drome, even those who have not experienced an attack of
AF, because atrial vulnerability is common and AF could
occur during the follow-up period.
Conclusions. This study showed that: 1) the incidences of
spontaneous and induced AF in patients with Brugada
syndrome were high; 2) atrial vulnerability was increased in
patients with Brugada syndrome; and 3) atrial vulnerability
was also increased in the Brugada syndrome patients with-
out spontaneous AF. Abnormal atrial conduction may play
an important role in the induction of AF in patients with
Brugada syndrome.
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